1079 related articles for article (PubMed ID: 31074374)
1. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
[TBL] [Abstract][Full Text] [Related]
2. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
3. Glutamine Metabolism Regulators Associated with Cancer Development and the Tumor Microenvironment: A Pan-Cancer Multi-Omics Analysis.
Zou J; Du K; Li S; Lu L; Mei J; Lin W; Deng M; Wei W; Guo R
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573287
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
[TBL] [Abstract][Full Text] [Related]
5. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Bulk RNA Sequencing Data Reveals Novel Transcription Factors Associated With Immune Infiltration Among Multiple Cancers.
Liu L; Zhao Q; Cheng C; Yi J; Sun H; Wang Q; Quan W; Xue Y; Sun L; Cong X; Zhang Y
Front Immunol; 2021; 12():644350. PubMed ID: 34489925
[TBL] [Abstract][Full Text] [Related]
7. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
Front Immunol; 2021; 12():812713. PubMed ID: 35069601
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers.
Zhang Y; Xu Y; Feng L; Li F; Sun Z; Wu T; Shi X; Li J; Li X
Oncotarget; 2016 Sep; 7(39):64148-64167. PubMed ID: 27580177
[TBL] [Abstract][Full Text] [Related]
9. Multi-Omics Pan-Cancer Analysis of Procollagen N-Propeptidase Gene Family of ADAMTS as Novel Biomarkers to Associate with Prognosis, Tumor Immune Microenvironment, Signaling Pathways, and Drug Sensitivities.
Chen Y; Xiao C; Fan Q; Zhang Y; Huang Q; Ou Y
Front Biosci (Landmark Ed); 2024 Apr; 29(4):151. PubMed ID: 38682182
[TBL] [Abstract][Full Text] [Related]
10. MS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune Microenvironment Based on TCGA Database Analysis.
Li S; Fang Y
Med Sci Monit; 2022 Jan; 28():e934597. PubMed ID: 35091527
[TBL] [Abstract][Full Text] [Related]
11. A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Yang X; Miao Y; Wang J; Mi D
Life Sci; 2021 May; 273():119307. PubMed ID: 33691171
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
13. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.
Chang WH; Lai AG
BMC Cancer; 2020 Aug; 20(1):773. PubMed ID: 32807122
[TBL] [Abstract][Full Text] [Related]
14. A pan-cancer analysis of driver gene mutations, DNA methylation and gene expressions reveals that chromatin remodeling is a major mechanism inducing global changes in cancer epigenomes.
Youn A; Kim KI; Rabadan R; Tycko B; Shen Y; Wang S
BMC Med Genomics; 2018 Nov; 11(1):98. PubMed ID: 30400878
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer.
Yuan Z; Li B; Liao W; Kang D; Deng X; Tang H; Xie J; Hu D; Chen A
Front Immunol; 2024; 15():1382520. PubMed ID: 38698857
[TBL] [Abstract][Full Text] [Related]
16. The pan-cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia.
Chang WH; Lai AG
Ann N Y Acad Sci; 2019 Jul; 1448(1):65-82. PubMed ID: 31215667
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive bioinformatics analysis of NOX4 as a biomarker for pan-cancer prognosis and immune infiltration.
Liu Y; Huang H; Yang X; Huang D; Wang X; Yuan M; Hong L
Aging (Albany NY); 2024 Apr; 16(8):7437-7447. PubMed ID: 38663913
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the role of Frizzled 2 in different cancer types.
Zhou M; Sun X; Zhu Y
FEBS Open Bio; 2021 Apr; 11(4):1195-1208. PubMed ID: 33565732
[TBL] [Abstract][Full Text] [Related]
19. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Bao R; Stapor D; Luke JJ
Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
[TBL] [Abstract][Full Text] [Related]
20. Pan-organ transcriptome variation across 21 cancer types.
Hu W; Yang Y; Li X; Zheng S
Oncotarget; 2017 Jan; 8(4):6809-6818. PubMed ID: 28036280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
